Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

Acute renal failure due to cast nephropathy (CAN) is a severe complication of multiple myeloma (MM). Here, we aimed to identify parameters associated with renal outcomes and survival in newly diagnosed MM patients with CAN-related acute renal failure and to validate the IMWG criteria for renal response. CAN diagnosis was based on biopsy or clinical assessment. Of 787 registered patients, 354 met the inclusion criteria, requiring at least two therapy cycles with documented chemotherapy response, renal response, and eGFR. Baseline free light chain (FLC) levels (median 6825.65 mg/L) decreased below 500 mg/L in 67.8% of patients. According to IMWG classification, renal complete response, partial response, and minimal response were achieved in 33.9%, 19.5%, and 28.0% of patients, respectively. The best eGFR values > 60 mL/min/1.73 m<sup>2</sup> were observed in 33.9% of patients, while 33.3%, 22.3%, and 10.5% had best eGFR values of 30-59, 15-29, and < 15 mL/min/1.73 m<sup>2</sup>, respectively. Renal response correlated with baseline FLC levels, IgG kappa, eGFR, and ECOG status in multivariate analysis, as well as with myeloma response and FLC reduction in univariate analysis. Median overall survival was 77.6 months. Survival correlated with age, myeloma response, ECOG status, FLC kappa type, baseline eGFR, standard-risk cytogenetics, and calcium levels, among other factors. A comparison of IMWG renal response criteria with classification based solely on best eGFR showed similar utility. Of 136 patients requiring dialysis, 80 (58.8%) were able to discontinue dialysis during therapy. Bortezomib containing myeloma therapy, along with significant FLC reduction, was associated with favorable outcome.

Authors

Institutions

Publication Details

Journal
American Journal of Hematology
Published
2025-10-24
DOI
https://doi.org/10.1002/ajh.70104
Citations
2
Primary Topic
Multiple Myeloma Research and Treatments
Type
article
Field-Weighted Citation Impact
3.54
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

Javier de la Rubia Comos, Hermine Agis, Nelson Leung, Kenar D. Jhaveri et al.
2 citations
American Journal of Hematology
Multiple Myeloma Research and Treatments
3.54
article

Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

Javier de la Rubia Comos, Hermine Agis, Nelson Leung, Kenar D. Jhaveri, Efstathios Kastritis, Luca Arcaini, Aristeidis Chaidos, Heinz Ludwig, Francesca Gay, Nattawat Klomjit, Meletios Athanasios Dimopoulos, Andrea Havasi, Evangelos Terpos, Sarah Bernhard, Silvia Mangiacavalli, Dario Roccatello, Güldane Cengiz Seval, Foteini Theodorakakou, Daniele Derudas, Wolfgang Hilbe, Frank Bridoux, Meral Beksac
article en
2 citations

Abstract

Acute renal failure due to cast nephropathy (CAN) is a severe complication of multiple myeloma (MM). Here, we aimed to identify parameters associated with renal outcomes and survival in newly diagnosed MM patients with CAN-related acute renal failure and to validate the IMWG criteria for renal response. CAN diagnosis was based on biopsy or clinical assessment. Of 787 registered patients, 354 met the inclusion criteria, requiring at least two therapy cycles with documented chemotherapy response, renal response, and eGFR. Baseline free light chain (FLC) levels (median 6825.65 mg/L) decreased below 500 mg/L in 67.8% of patients. According to IMWG classification, renal complete response, partial response, and minimal response were achieved in 33.9%, 19.5%, and 28.0% of patients, respectively. The best eGFR values > 60 mL/min/1.73 m<sup>2</sup> were observed in 33.9% of patients, while 33.3%, 22.3%, and 10.5% had best eGFR values of 30-59, 15-29, and < 15 mL/min/1.73 m<sup>2</sup>, respectively. Renal response correlated with baseline FLC levels, IgG kappa, eGFR, and ECOG status in multivariate analysis, as well as with myeloma response and FLC reduction in univariate analysis. Median overall survival was 77.6 months. Survival correlated with age, myeloma response, ECOG status, FLC kappa type, baseline eGFR, standard-risk cytogenetics, and calcium levels, among other factors. A comparison of IMWG renal response criteria with classification based solely on best eGFR showed similar utility. Of 136 patients requiring dialysis, 80 (58.8%) were able to discontinue dialysis during therapy. Bortezomib containing myeloma therapy, along with significant FLC reduction, was associated with favorable outcome.

American Journal of HematologyVol. 101(1)
Boston University (US), University of Minnesota (US), Mayo Clinic (US), Hofstra University (US), Ankara University (TR), Imperial College Healthcare NHS Trust (GB), Korea University (KR), National and Kapodistrian University of Athens (GR), University of Pavia (IT), Valencia Catholic University Saint Vincent Martyr (ES), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), Wilhelminen Hospital (AT), Centre Hospitalier Universitaire de Poitiers (FR), Ospedale San Giovanni Bosco (IT), Hypertension Institute (US), Policlinico San Matteo Fondazione (IT), Instituto de Investigación Sanitaria La Fe (ES), Medical University of Vienna (AT)
Openalex Percentile: Top 6%
Multiple Myeloma Research and Treatments
3.54
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.